

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During consultation, one stakeholder, noted that ovarian cancer is more common in women over 50 and that cancer is considered a disability under the Equality Act 2010. Therefore age, gender and disability are all relevant protected characteristics for the purpose of this appraisal.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

If appropriate, consideration may be given to characteristics that are shared by people with advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy with bevacizumab, and are protected under equality legislation (including age, gender and disability).

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not applicable.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name):Janet Robertson.....

Date: 30 January 2020